Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04148937
Title A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

lung cancer

breast cancer

ovarian cancer

prostate cancer

kidney cancer

melanoma

pancreatic cancer

Therapies

LY3475070

LY3475070 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Sarah Cannon Research Institute at HealthOne Denver Colorado 80218 United States Details
Florida Cancer Specialists ORLANDO/DDU Lake Mary Florida 32746 United States Details
START Midwest Grand Rapids Michigan 49546 United States Details
Washington University Medical School Saint Louis Missouri 63110 United States Details
Cleveland Clinic Foundation Cleveland Ohio 44195 United States Details
Sarah Cannon Research Institute SCRI Nashville Tennessee 37203 United States Details
University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
Peter MacCallum Cancer Centre Melbourne Victoria 3000 Australia Details
Addenbrookes Hospital Cambridge Cambridgeshire CB2 0QQ United Kingdom Details
Beatson West of Scotland Cancer Center Glasgow Scotland G12 0YN United Kingdom Details
Christie NHS Foundation Trust Manchester M20 4 BX United Kingdom Details
Royal Marsden NHS Trust Sutton SM2 5PT United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field